ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) released its quarterly earnings results on Monday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.10, Zacks reports.
ESSA Pharma Trading Down 2.2 %
Shares of ESSA Pharma stock traded down $0.10 on Tuesday, hitting $4.53. 28,170 shares of the company traded hands, compared to its average volume of 95,496. ESSA Pharma has a 52 week low of $2.58 and a 52 week high of $11.67. The company has a market cap of $200.95 million, a PE ratio of -7.29 and a beta of 1.82. The stock’s 50 day moving average price is $5.30 and its 200-day moving average price is $7.08.
Analyst Upgrades and Downgrades
Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of ESSA Pharma in a research note on Thursday, May 16th.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
See Also
- Five stocks we like better than ESSA Pharma
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Which Wall Street Analysts are the Most Accurate?
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- What is a Dividend King?
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
